108985
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
黏液纤维肉瘤复发对生存预后的影响及关键危险因素：一项单中心回顾性研究
Authors Guo Q, Xu X, Yang Z, Wang K, Wu J, Liu B, Tao H, Ye Z
Received 9 April 2025
Accepted for publication 8 October 2025
Published 22 October 2025 Volume 2025:18 Pages 3425—3436
DOI https://doi.org/10.2147/RMHP.S533390
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Jongwha Chang
Qinghe Guo,1– 4,* Xianming Xu,5,* Zhengming Yang,1– 4 Keyi Wang,1,2 Jiadan Wu,1,2 Bing Liu,1– 4 Huimin Tao,1– 4 Zhaoming Ye1– 4
1Department of orthopedics, The Second Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, 310000, People’s Republic of China; 2Orthopedics Research Institute of Zhejiang University, Hangzhou, Zhejiang Province, 310000, People’s Republic of China; 3Clinical Research Center of Motor System Disease of Zhejiang Province, Hangzhou, 310000, People’s Republic of China; 4State Key Laboratory of Transvascular Implantation Devices, Hangzhou, 310009, People’s Republic of China; 5Department of Orthopedics, Longquan People’s Hospital, Lishui, Zhejiang Province, 323700, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Zhengming Yang, Department of orthopedics, The Second Affiliated Hospital of Zhejiang University, No. 1504 of Jiang Hon Road, BinJiang District, Hangzhou, 310000, People’s Republic of China, Tel +86 13758228633, Email 2200013@zju.edu.cn Qinghe Guo, State Key Laboratory of Transvascular Implantation Devices, Hangzhou, Zhejiang Province, 310009, People’s Republic of China, Email 471421@zju.edu.cn
Objective: Myxofibrosarcoma (MFS) is a rare malignant fibrogenic soft tissue tumor with high propensity for recurrence. This study retrospectively analyzed the surgical treatment outcomes of patients with myxofibrosarcoma (MFS) at a single center to evaluate the impact of recurrence on survival prognosis.
Methods: Clinical data from 80 patients who underwent surgical treatment for MFS between January 2015 and January 2023 were reviewed retrospectively. Postoperative follow-up was conducted to assess recurrence and overall survival. Kaplan-Meier survival analysis was used to estimate overall survival (OS) and compare survival curves. Patients were stratified into recurrence and recurrence-free groups based on recurrence status. Oncological prognosis, prognostic factors influencing survival and recurrence, and the association between recurrence and survival prognosis were examined.
Results: Over a median follow-up period of 40.6 months, recurrence was observed in 38 patients (47.5%), including 16 patients with multiple recurrences. A total of 17 patients (21.3%) died, and the 5-year OS rate was 70.1%. Independent prognostic factors for OS included age, tumor size, and chemotherapy. The presence of a tumor adjacent to a major vessel or nerve, as well as involvement of the upper extremity, were identified as independent risk factors for recurrence. No statistically significant differences in survival prognosis were observed between patients with and without recurrence. Additionally, survival outcomes did not differ significantly between patients with a single recurrence and those with multiple recurrences.
Conclusion: MFS exhibits a high recurrence rate, with multiple recurrences frequently occurring within three years postoperatively. However, both single and multiple recurrences, when managed with aggressive surgical intervention, may not had an adverse effect on overall survival. For tumors located near major vessels or nerves, achieving complete surgical resection and maintaining vigilant postoperative surveillance are essential to mitigate the risk of recurrence.
Keywords: neoplasms malignant, myxofibrosarcoma, survival time, disease recurrence, prognosis
1Department of orthopedics, The Second Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, 310000, People’s Republic of China; 2Orthopedics Research Institute of Zhejiang University, Hangzhou, Zhejiang Province, 310000, People’s Republic of China; 3Clinical Research Center of Motor System Disease of Zhejiang Province, Hangzhou, 310000, People’s Republic of China; 4State Key Laboratory of Transvascular Implantation Devices, Hangzhou, 310009, People’s Republic of China; 5Department of Orthopedics, Longquan People’s Hospital, Lishui, Zhejiang Province, 323700, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Zhengming Yang, Department of orthopedics, The Second Affiliated Hospital of Zhejiang University, No. 1504 of Jiang Hon Road, BinJiang District, Hangzhou, 310000, People’s Republic of China, Tel +86 13758228633, Email 2200013@zju.edu.cn Qinghe Guo, State Key Laboratory of Transvascular Implantation Devices, Hangzhou, Zhejiang Province, 310009, People’s Republic of China, Email 471421@zju.edu.cn
Objective: Myxofibrosarcoma (MFS) is a rare malignant fibrogenic soft tissue tumor with high propensity for recurrence. This study retrospectively analyzed the surgical treatment outcomes of patients with myxofibrosarcoma (MFS) at a single center to evaluate the impact of recurrence on survival prognosis.
Methods: Clinical data from 80 patients who underwent surgical treatment for MFS between January 2015 and January 2023 were reviewed retrospectively. Postoperative follow-up was conducted to assess recurrence and overall survival. Kaplan-Meier survival analysis was used to estimate overall survival (OS) and compare survival curves. Patients were stratified into recurrence and recurrence-free groups based on recurrence status. Oncological prognosis, prognostic factors influencing survival and recurrence, and the association between recurrence and survival prognosis were examined.
Results: Over a median follow-up period of 40.6 months, recurrence was observed in 38 patients (47.5%), including 16 patients with multiple recurrences. A total of 17 patients (21.3%) died, and the 5-year OS rate was 70.1%. Independent prognostic factors for OS included age, tumor size, and chemotherapy. The presence of a tumor adjacent to a major vessel or nerve, as well as involvement of the upper extremity, were identified as independent risk factors for recurrence. No statistically significant differences in survival prognosis were observed between patients with and without recurrence. Additionally, survival outcomes did not differ significantly between patients with a single recurrence and those with multiple recurrences.
Conclusion: MFS exhibits a high recurrence rate, with multiple recurrences frequently occurring within three years postoperatively. However, both single and multiple recurrences, when managed with aggressive surgical intervention, may not had an adverse effect on overall survival. For tumors located near major vessels or nerves, achieving complete surgical resection and maintaining vigilant postoperative surveillance are essential to mitigate the risk of recurrence.
Keywords: neoplasms malignant, myxofibrosarcoma, survival time, disease recurrence, prognosis